Delving into the Latest Updates on Mequitazine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Butix, Histacoid, Mequitazine (JP17/INN)

+ [15]

Target

H1 receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [3]

Active Indication

Conjunctivitis, AllergicAsthmaDermatitis+ [5]

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (07 Oct 1982),

DermatitisEczemaPruritus+ [2]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H22N2S

InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N

CAS Registry29216-28-2

In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)

Start Date01 Mar 2025

Sponsor / Collaborator

King's College London

ITMCTR2024000148

/ SuspendedNot ApplicableIIT

Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury

Start Date01 Nov 2024

Sponsor / Collaborator-

CTRI/2024/10/075516

/ Not yet recruitingNot Applicable

Influence of Myofascial Release and Remote Myofascial Release on Gait and Muscle Activation In Asymptomatic Hamstring Muscle Tightness - NIL

Start Date28 Oct 2024

Sponsor / Collaborator

Jamia Millia Islamia

100 Clinical Results associated with Mequitazine

Login to view more data

100 Translational Medicine associated with Mequitazine

Login to view more data

100 Patents (Medical) associated with Mequitazine

Login to view more data

370

Literatures (Medical) associated with Mequitazine

04 Nov 2024·Chemistry – A European Journal

Overriding Cage Effect in Electron Donor‐Acceptor Photoactivation of Diaryliodonium Reagents: Synthesis of Chalcogenides

Article

Author: Murarka, Sandip ; Mahapatra, Sanat Kumar ; Parida, Sushanta Kumar ; Roy, Lisa ; Meher, Prahallad

AbstractIn recent times, diaryliodonium reagents (DAIRs) have witnessed a resurgence as arylating reagents, especially under photoinduced conditions. However, reactions proceeding through electron donor‐acceptor (EDA) complex formation with DAIRs are restricted to electron‐rich reacting partners serving as donors due to the well‐known cage effect. We discovered a practical and high‐yielding visible‐light‐induced EDA platform to generate aryl radicals from the corresponding DAIRs and use them to synthesize key chalcogenides. In this process, an array of DAIRs and dichalcogenides react in the presence of 1,4 diazabicyclo[2.2.2]octane (DABCO) as a cheap and readily available donor, furnishing a variety of di(hetero)aryl and aryl/alkyl chalcogenides in good yields. The method is scalable, features a broad scope with good yields, and operates under open‐to‐air conditions. The photoinduced chalcogenation technology is suitable for late‐stage functionalizations and disulfide bioconjugations and facilitates access to biologically relevant thioesters, dithiocarbamates, sulfoximines, and sulfones. Moreover, the method applies to synthesizing diverse pharmaceuticals, such as vortioxetine, promazine, mequitazine, and dapsone, under amenable conditions.

01 Jul 2024·Journal of Forensic Sciences

Analysis of unknown (unlabeled/mislabeled) drug products for active pharmaceutical ingredients and related substances by an international mail facility satellite laboratory equipped with rapid screening devices

Article

Author: Morales‐Garcia, Flavia ; Collins, Melissa ; Gonzalez Illan, Fernando ; LaGarde, Donna ; Loh, Mark ; Reimer, Allison M. ; Wetherby, Anthony E. ; Batson, JaCinta ; Howe, Gregory ; Lanzarotta, Adam ; Sterling, Megan E. ; Kern, Sara ; Arrecis, Julio ; Lorenz, Lisa ; Hudson‐Davis, Morgan ; Kimani, Martin ; Thatcher, Michael ; Altaf, Muhammad ; Boyd, Brian ; Griffin, Kelsey M. ; Laguerre, David ; Patel, Anvi

AbstractTwo chemists employed a three‐device rapid screening “toolkit” consisting of a handheld Raman spectrometer, transportable mass spectrometer, and portable Fourier transform infrared (FT‐IR) spectrometer at an international mail facility (IMF) satellite laboratory to examine unknown (unlabeled/mislabeled) products for the presence of active pharmaceutical ingredients (APIs). Phase I of this project previously demonstrated that this toolkit was the most effective collection of instruments for identifying APIs in product types collected at IMFs during a nationwide mail blitz and Phase II of this project previously demonstrated that results generated using the toolkit during a satellite laboratory pilot program were as reliable as those generated by a full‐service library when two or more of these instruments identify an API. This study (Phase III) described the results of the satellite laboratory toolkit during production mode and encompassed the period ranging from June 2021 through December 2022. During this study, a total of 858 products were examined on‐site at the IMF. The satellite laboratory yielded conclusive results for 726 (84.6%) products, which were used to support regulatory action, and identified 132 (15.4%) products that required additional full‐service laboratory analyses due to inconclusive results. The satellite and full‐service laboratory verified/confirmed at least one API/related substance in 617 (71.9%) products. A total of 709 APIs/related substances were found in the 617 products, and 202 of these 709 compounds were unique/different. Overall, during Phases I through III of this program, 350 different substances have been identified in products collected at IMFs.

01 Jul 2024·Journal of Chromatography A

Trace analysis of 20 antihistamines in milk by ultrahigh performance liquid chromatography coupled with high field quadrupole orbitrap high resolution mass spectrometry followed dispersive micro solid phase extraction

Article

Author: Zhiming, Xiao ; Wuyan, Liu ; Junming, Wang ; Decheng, Suo ; Xia, Fan ; Yang, Li ; Zhanteng, Song

Ultrahigh-performance liquid chromatography coupled with high-field quadrupole Orbitrap high resolution mass spectrometry was used for the separation and determination of 20 antihistamines, and a dispersive micro solid-phase extraction procedure using high-performance absorbing material was developed as a sample preparation strategy for extracting 20 antihistamines from milk. Instrument conditions and key parameters influencing extraction efficiency were investigated to obtain an optimized method. The limit of detection for 20 antihistamines in milk using this method is 0.05 µg/L to 1.0 µg/L. Recoveries are between 80.7 % and 108.3 %, and the relative standard deviation is less than 15 %. It is suitable for confirmatory monitoring and quantitative analysis of 20 antihistamines in milk. The results show that antihistamines in milk may be noteworthy issues for human health and environmental pollution.

100 Deals associated with Mequitazine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01324	Mequitazine	R06AD07	DB01071

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Conjunctivitis, Allergic	New Zealand	-	09 Jul 1999
Asthma	Japan	Asahi Kasei Corp.	30 Mar 1990
Asthma	Japan	Alfresa Pharma Corp.	30 Mar 1990
Dermatitis	Japan	Asahi Kasei Corp.	07 Oct 1982
Eczema	Japan	Asahi Kasei Corp.	07 Oct 1982
Pruritus	Japan	Asahi Kasei Corp.	07 Oct 1982
Pruritus	Japan	Alfresa Pharma Corp.	07 Oct 1982
Rhinitis, Allergic	Japan	Alfresa Pharma Corp.	07 Oct 1982
Rhinitis, Allergic	Japan	Asahi Kasei Corp.	07 Oct 1982
Urticaria	Japan	Asahi Kasei Corp.	07 Oct 1982
Urticaria	Japan	Alfresa Pharma Corp.	07 Oct 1982
Rhinitis	-	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Not Applicable	Vaso-occlusive crisis	200	Immediate-Release (IR) opioids	xdtuyeqxwc(agbvbkgbqg) = jpwttyldyv audwouiiob (hgbdutmwns )	-	10 Dec 2023
				Extended-Release (ER) opioids	xdtuyeqxwc(agbvbkgbqg) = vgprvzchrg audwouiiob (hgbdutmwns )
DDW2022	Not Applicable	Metabolic Diseases	-	highly functional duodenal stent with controlled radical oxygen species release (Control group (no PDT stent))	phmqxiqiox(curzpzvsjk) = PDT was applied with no evidence of early stricture, pancreatitis, or hemorrhage in all 8 pigs lklzjoycmh (sstrpjyhzb ) View more	-	21 May 2022
MO1009 (ERA2022)	Not Applicable	Delayed renal graft function	-	Immediate-Release Tacrolimus (IR-Tac)	(mszgoatraw) = bofzehmjdb blejkxzruz (udhhrsfnyp )	Positive	03 May 2022
				LCP-Tac (LCPT)	(mszgoatraw) = liniybggsx blejkxzruz (udhhrsfnyp )
ASTRO2020	Not Applicable	Neoplasms	-	Nanoparticle-Mediated Radiation-Triggered Release Of Nitrate (AuNP@nIm-CPP)	uqqpxxgeuo(tsjfkafgct) = rfjrntqmoq cjazjecbhq (xtjlazevbl )	-	01 Nov 2020
				Nanoparticle-Mediated Radiation-Triggered Release Of Nitrate (AuNP@CPP)	uqqpxxgeuo(tsjfkafgct) = nnbhbogihq cjazjecbhq (xtjlazevbl )
TRANSFORM study (ERA2020)	Not Applicable	Renal transplant rejection	38	Twice-daily Tacrolimus (TAC-IR) + Everolimus (EVR) + Corticosteroid	cacemofzlx(khqqafoyvo) = qvxmtontli qpktsqhscb (kuitnlwstb, 6.4 - 9.5) View more	Positive	06 Jun 2020
				Once-daily Extended Release Tacrolimus (LCPT) + Everolimus (EVR) + Corticosteroid	cacemofzlx(khqqafoyvo) = dzzflgjgfo qpktsqhscb (kuitnlwstb, 5.4 - 8.7) View more
WCN2019	Not Applicable	REM Sleep Behavior Disorder First line	40	Prolonged-release melatonin 2mg	jpelinbkvu(ijonijgboc) = nhezigohpo nhjvvwpgft (dgngvfzixz )	-	15 Oct 2019
				Clonazepam 0.5mg	jpelinbkvu(ijonijgboc) = xryzecvohq nhjvvwpgft (dgngvfzixz )
PO115 (AAO2019)	Not Applicable	Keratitis Maintenance	-	Novel In Situ Sustained-Release Drug Delivery System	wonhdksjsg(jchpymcffr) = mmuqtybare nmtyhdmomv (tgqifahute )	Positive	12 Oct 2019
ERA2018	Not Applicable	-	-	Extended Release Tacrolimus (LCPT-ER)	(bovuiwdpai) = lqbolmvcrg hhiiukmuxr (dyeqkpqadr ) View more	-	18 May 2018
				Immediate-Release Tacrolimus (TAC-IR)	(bovuiwdpai) = szolzalyoq hhiiukmuxr (dyeqkpqadr )
NCT00934661 (CTgov)	Phase 4	-	40	Extended Release Epidural Morphine (EREM) (Extended Release Epidural Morphine)	outmeossve(qjqsfoqyst) = ssvjwmobzt igeplisdkv (dxymfsdtcz, jmgxqodzjy - ucyrrwwaej) View more	-	16 Jan 2018
				Placebo (Placebo Group)	outmeossve(qjqsfoqyst) = tmvbdtbsox igeplisdkv (dxymfsdtcz, kyxiqveptq - udjzmvdhpg) View more
CNS2015	Not Applicable	Attention Deficit Disorder With Hyperactivity	45	Methylphenidate Extended-Release Oral Suspension (MEROS)	tfzhoprpiw(cemgnpecby) = rsrvenhxgo csvmgpyzff (uejpccbpis ) View more	Positive	25 Sep 2015